Valid Ghana · FDA Ghana

POLY M&B INJECTION

Polymyxin B Sulphate

FDA/SD.245-081410 Polymyxin B Sulphate 500,000 units

What it does

Polymyxin is an antibiotic used to treat serious infections caused by certain bacteria.

Commonly used for: serious bacterial infections, infections caused by gram-negative bacteria

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.245-081410
Registration date
2024-08-26
Expiry date
2029-09-01
Status
Valid
Active ingredient
Polymyxin B Sulphate
Dosage form
Polymyxin B Sulphate
Strength
500,000 units
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Bharat Serums & Vaccines
Country of origin
INDIA

Source: Food and Drugs Authority · fetched 2026-04-18 08:33:04 · updated 2026-09-18 04:00:13

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Polymyxin is an antibiotic used to treat serious infections caused by certain bacteria.

What it treats

  • serious bacterial infections
  • infections caused by gram-negative bacteria

How it works

Polymyxin works by attacking the outer membrane of bacteria, causing them to break apart and die.

Who it's for

It is used for people with severe infections that do not respond to other antibiotics.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: polymyxin

Polymyxin is an antibiotic that belongs to the polymyxin class of antibiotics. It is primarily used for the treatment of infections caused by gram-negative bacteria, particularly those resistant to other antibiotics. Polymyxin is typically used in a clinical setting for serious infections due to its nephrotoxicity and neurotoxicity, which limits its use to severe cases where no alternatives are available.

Indications

  • Pneumonia caused by multidrug-resistant gram-negative bacteria
  • Septicemia caused by gram-negative bacteria
  • Urinary tract infections caused by resistant organisms
  • Skin infections caused by resistant gram-negative bacteria

Dosage

Children: Refer to BNF for Children for appropriate dosing in paediatric patients.

Adults: Refer to local guidelines or BNF for specific dosing recommendations based on the type and severity of infection.

Mechanism of action

Polymyxin exerts its antibacterial effect by disrupting the integrity of the bacterial cell membrane. It binds to the lipopolysaccharides and phospholipids in the outer membrane of gram-negative bacteria, leading to increased permeability and eventual cell lysis.

Pharmacodynamics

Polymyxin has a bactericidal effect against susceptible gram-negative organisms. Its action is concentration-dependent, with higher concentrations leading to a more significant bactericidal effect. Resistance can occur through modifications in the bacterial cell membrane components that reduce drug binding.

Pharmacokinetics

Polymyxin is poorly absorbed from the gastrointestinal tract and is typically administered parenterally (intravenously or intramuscularly) for systemic infections. It has a volume of distribution that suggests extensive tissue penetration but is primarily eliminated by the kidneys. Half-life varies based on renal function, and dose adjustments may be necessary in patients with renal impairment.

Adverse effects

  • Nephrotoxicity
  • Neurotoxicity
  • Allergic reactions
  • Respiratory distress
  • Nausea
  • Vomiting

Interactions

  • Increased nephrotoxicity when used with other nephrotoxic agents such as aminoglycosides or cisplatin
  • Potential for respiratory depression with neuromuscular blocking agents

Precautions

  • Use with caution in patients with renal impairment
  • Monitor renal function during therapy
  • Consider the risk of neurotoxicity, especially with prolonged use

Pregnancy

Polymyxin is classified as category C. Its safety during pregnancy has not been established, thus it should only be used if clearly needed.

Breast-feeding

It is not known if polymyxin is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Protect from freezing.

Formulations

  • Polymyxin B sulfate injection
  • Polymyxin E (colistin) inhalation solution
  • Topical formulations

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.